stockrowCollPlant Biotechnologies Ltd. Sponsored ADR
CLGN Healthcare Biotechnology
CollPlant Biotechnologies Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, up 360.4% from fiscal 2024.
- Revenue
- −39.7%
- EPS
- +32.5%
- Free cash flow
- +5.08%
Quarter to June 2026, against a year earlier
Follow CLGN
Alert me
CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) EV/Sales
As of 6 November 2026, CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN) trades at a EV/Sales of 25.3×. Over the past ten years it has ranged from 0.0× (September 2017) to 398× (January 2023); the current reading is higher than 63% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.0× | (89.57%) |
| FY2024 | 67.1× | 1,448.86% |
| FY2023 | 4.3× | (98.17%) |
| FY2022 | 236× | 2,851.58% |
| FY2021 | 8.0× | (35.58%) |
| FY2020 | 12.4× | (4.25%) |
| FY2019 | 13.0× | 402.48% |
| FY2018 | 2.6× | (95.03%) |
| FY2017 | 51.9× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 23.7× | 12.53% |
| Mar 2026 | 21.1× | 201.15% |
| Dec 2025 | 7.0× | (43.87%) |
| Sep 2025 | 12.5× | 203.94% |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VTGN VistaGen Therapeutics, Inc. compare | −6.4× |
| SNGX Soligenix Inc. compare | −4.1× |
| KPRX Kiora Pharmaceuticals, Inc. compare | −0.4× |
| CRIS Curis, Inc. compare | −0.3× |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| TOVX Theriva Biologics, Inc. compare | n/m |
| LEXX Lexaria Bioscience Corp. compare | 6.1× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR | 26.1× |
| TCRT Alaunos Therapeutics, Inc. compare | 1,410× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)